Which patents cover Clinimix E 2.75/10 Sulfite Free W/ Elect In Dextrose 10% W/ Calcium In Plastic Container, and what generic alternatives are available?
Clinimix E 2.75/10 Sulfite Free W/ Elect In Dextrose 10% W/ Calcium In Plastic Container is a drug marketed by Baxter Hlthcare and is included in one NDA.
Investment Scenario and Fundamentals Analysis for CLINIMIX E 2.75/10 Sulfite-Free with Electrolytes in Dextrose 10% with Calcium
Last updated: February 15, 2026
Overview
CLINIMIX E 2.75/10 is a proprietary parenteral nutrition (PN) formulation administered via intravenous infusion. Marketed as sulfite-free, with added electrolytes, dextrose, and calcium, it targets clinical settings requiring customized nutritional support. As a pharmaceutical product, it operates within the specialized infusion and nutritional sector, primarily supplied to hospitals and healthcare facilities.
Sodium, potassium, magnesium, calcium for electrolyte balance.
Sulfite-free formulation ensures compatibility across sensitive patient populations.
Electrolytes' precise quantities are tailored for clinical efficacy.
Container:
Plastic container, designed for compatibility and stability in hospital settings.
Single-use, sterile package conforms to regulatory standards for infusion products.
Technical Specifications
Attribute
Specification
Strengths
2.75 g/100 ml of amino acids and 10 g/100 ml of dextrose (assumed based on typical formulations)
Sulfite content
Zero, suitable for sulfite-sensitive patients
Additives
Electrolytes and calcium as per formulation standards
Packaging
Plastic container, sterile, typically 250 ml or 500 ml
Regulatory Landscape
Approval & Compliance:
Approved by regulatory agencies (FDA, EMA, etc.) for hospital use.
Must comply with USP/NF standards for infusion solutions.
Manufacturing Standards:
GMP-compliant manufacturing facilities.
Stability and compatibility testing support shelf life (~24 months).
Market Dynamics
Target Market
Hospitals, clinics, and specialty care centers.
Patients requiring long-term or specialized nutritional supplementation.
Market Size & Growth
The global parenteral nutrition market was valued at USD 9.7 billion in 2022.
CAGR projected at around 7% through 2030.[1]
Growth driven by aging populations, rising prevalence of malnutrition, and advances in clinical nutrition.
Competitive Landscape
Major players include Baxter, Fresenius, B. Braun, and ICU Medical.
CLINIMIX E 2.75/10’s sulfite-free feature and electrolyte customization distinguish it.
Portfolio diversification involves ingredients balancing efficacy and safety standards.
Investment Considerations
Strengths
Market Demand: High, driven by increasing nutritional support needs.
Regulatory Approvals: Established compliance pathways reduce market entry barriers.
Product Differentiation: Sulfite-free and electrolyte customization appealing to niche segments.
Challenges
Intense Competition: Market dominated by large, well-established firms.
Manufacturing Complexity: Strict GMP and stability requirements increase costs.
Pricing Pressures: Managed care and hospital procurement contracts limit margins.
Growth Opportunities
New Formulations: Incorporation of novel nutrients or flavors.
Regional Expansion: Access to emerging markets with growing healthcare budgets.
Partnerships & Distribution: Strategic alliances with hospital supply chains.
Financial and Investment Metrics
Pricing Range: Typically USD 15–25 per 250 ml container.
Cost of Goods Sold (COGS): Estimated at 30–40%, influenced by raw materials and manufacturing costs.
Market Penetration: Limited, due to hospital procurement cycles and clinical adoption rates.
Margins: Target gross margins of 40–50%, with potential for variation based on scale and negotiations.
Regulatory & Ethical Factors
Ensuring ongoing compliance with evolving standards.
Monitoring adverse event reporting and pharmacovigilance.
Adoption of environmentally sustainable packaging practices.
Risks and Mitigants
Risk
Mitigant
Regulatory delays
Early engagement with regulators
Supply chain disruptions
Multiple sourcing, inventory buffering
Competition
Differentiation through product features and service
Key Takeaways
The product's niche features and clinical utility position it favorably within the parenteral nutrition market.
Market growth aligns with rising healthcare needs but is counterbalanced by stiff competition.
Cost management and strategic regional expansion are critical for profitability.
Continuous compliance and innovation sustain competitive advantage.
FAQs
What is the primary benefit of CLINIMIX E 2.75/10 being sulfite-free?
It reduces the risk of allergic reactions in sulfite-sensitive patients, broadening its clinical suitability.
How does its electrolyte composition compare to competitors?
The formulation offers tailored electrolyte levels, which may be customized further—setting it apart from standard products with fixed compositions.
What regulatory hurdles exist for market expansion?
Compliance with regional standards, local registration, and clinical validation are prerequisites for new markets.
Is this product suitable for outpatient use?
Primarily designed for hospital infusion settings; outpatient use is limited due to administration requirements.
What are the key factors influencing its market success?
Product differentiation, hospital procurement contracts, and alignment with clinical nutrition guidelines.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
